

 Early Warning System

IFC-41947

Jointown Pharma



## Quick Facts

<b>Countries</b>	China
<b>Financial Institutions</b>	International Finance Corporation (IFC)
<b>Status</b>	Proposed
<b>Bank Risk Rating</b>	B
<b>Borrower</b>	JOINTOWN PHARMACEUTICAL GROUP CO., LTD.
<b>Sectors</b>	Industry and Trade
<b>Investment Type(s)</b>	Loan
<b>Investment Amount (USD)</b>	\$ 150.00 million
<b>Loan Amount (USD)</b>	\$ 150.00 million
<b>Project Cost (USD)</b>	\$ 150.00 million



---

## Project Description

According to the bank's website, Jointown Pharmaceutical Group Co., Ltd. (“Jointown” or the “company”) is a major pharmaceutical product distribution company founded in 1999 in China with its headquarter based in Wuhan province and is publicly listed on the Stock Exchange of Shanghai (600998 SHA), with 31 provincial level and 94 prefecture-level pharmaceutical product distribution and logistics centers throughout China.

IFC is looking at providing debt financing to Jointown of up to RMB\$1 billion to support its expansion through the construction of up to 5 new product distribution centers and upgrading of 4 existing warehouses in China (the “project”).



---

## Investment Description

- International Finance Corporation (IFC)

## Private Actors

- [Jointown Pharmaceutical Group Co., Ltd.](#) -- Implementing Company

The company procures pharmaceutical products and medical equipment, stores in its large network of logistical centers in China, to be subsequently sold to hospitals, clinics, and pharmacies throughout China. While product distribution constitutes the core predominant part of the company's overall business, Jointown also owns and operates one manufacturing facility in the Beijing area (which produces diabetes and cardiovascular-related medications), and one in Zibo city, Shandong province (which produces medications for mental illnesses, diabetes, and cardiovascular conditions).



---

## Contact Information

### ACCOUNTABILITY MECHANISM OF IFC

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at [CAO@worldbankgroup.org](mailto:CAO@worldbankgroup.org). You can learn more about the CAO and how to file a complaint at <http://www.cao-ombudsman.org/>